15 Best S&P 500 Dividend Stocks to Buy Now

Page 11 of 13

3. Johnson & Johnson (NYSE:JNJ)

Number of Hedge Fund Holders: 98

Johnson & Johnson (NYSE:JNJ) is a New Jersey-based pharmaceutical company that operates through its subsidiaries to develop, manufacture, and market a wide range of healthcare products. Its diverse portfolio includes more than 10 high-performing drugs across various therapeutic areas, such as infectious diseases and oncology. Beyond pharmaceuticals, the company is also a key player in the medical device sector, providing additional diversification. Its financial performance has remained stable and consistent over time. The stock has surged by more than 14% in the past 12 months.

In the fourth quarter of 2024, Johnson & Johnson (NYSE:JNJ) reported revenue of $22.5 billion, reflecting a 5.2% increase year-over-year. As a leading healthcare company, it continues to focus on addressing diseases with significant unmet medical needs, including multiple myeloma, lung cancer, inflammatory bowel disease, and heart failure. The MedTech segment saw global operational sales rise by 6.2%, with acquisitions and divestitures accounting for 1.5% of this growth. Increased demand for electrophysiology products and Abiomed contributed to growth in the Cardiovascular division, while sales of wound closure products supported gains in the General Surgery segment.

Johnson & Johnson (NYSE:JNJ)’s quarterly dividend stands at $1.24 per share, offering a dividend yield of 3.01%, as of February 26. With a 62-year track record of consecutive dividend increases, the company remains one of the most consistent dividend payers in the market.

Page 11 of 13